

Company Overview

OncoSec Medical Incorporated is a biopharmaceutical company developing its investigational Intratumoral IL-12 intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of Intratumoral IL-12 have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating Intratumoral IL-12 for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate Intratumoral IL-12 in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.

OncoSec Provides Outlook for Second Half of 2018

Jun 28 2018, 8:00 AM EDT

OncoSec Added to the Russell Microcap® Index

Jun 25 2018, 8:00 AM EDT

OncoSec Presents Update on PISCES/KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial in Combination with Merck's KEYTRUDA® for Metastatic Melanoma at the ASCO 2018 Annual Meeting

Jun 4 2018, 8:00 AM EDT

Stock Overview

Symbol	ONCS
Exchange	Nasdaq
Market Cap	68.05m
Last Price	\$1.30
52-Week	\$0.88 - \$2.95

07/13/2018 04:00 PM EDT

Investor Relations

T: 855-ONCOSEC (855-662-6732)
investors@oncosec.com

Management Team

Daniel J. O'Connor

Chief Executive Officer, President and Director

Richard B. Slansky

Chief Financial Officer

Christopher G. Twitty, Ph.D.

Chief Scientific Officer

Sharron Gargosky, PhD

Chief Clinical and Regulatory Officer

OncoSec Medical Incorporated

3565 General Atomics Ct.
San Diego, CS 92121

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.